Latham & Watkins’ Post

Vista Equity Partners, an American private equity firm, agreed to acquire Model N, a provider of revenue optimization and compliance for pharmaceutical, medtech, and high-tech innovators, for $1.25bn. "We are pleased to have reached this agreement with Vista, which is the culmination of a robust sale process led by our Board of Directors with the assistance of our financial and legal advisors. As the Board considered the long-term path for Model N, we unanimously determined that the transaction with Vista represents the best opportunity to deliver compelling, certain, and immediate cash value to our stockholders and is in their best interest in light of the challenges faced by Model N as a standalone public company," Baljit Dail, Model N Chairman of the Board. Model N (led by Baljit Dail, Jason Blessing, and John Ederer) is advised by Jefferies and Fenwick & West. Vista Equity Partners (led by Nick Prickel) is advised by Kirkland & Ellis. #MergersAcquisitionsDivestitures #PrivateEquity #Software

In biotech acquisitions, technical due diligence is critical. A major key component is accurate Cost of Goods Manufactured (COGM) analysis. If you are looking to invest in biotech, check out this BDO insight for a comprehensive checklist on technical due diligence. At BPTG (a BDO life sciences consulting group), we specialize in precise COGM analysis, providing insights that private equity firms need to make informed decisions. For expert support in biotech M&A, discover how our globally-recognized bioprocess economic modeling team can help. #MAndA #Biotech #cogm #bioprocess #processeconomics #economicmodeling

Our own Oliver Schlueter, Novaliq CFO, on the panel discussing M&A and IPO strategies at H.C. Wainwright & Co., LLC and Goodwin Ernst & Young „Biotech on Tap“. Europe is a great place with great innovation. But we need a better financial European ecosystem to really benefit from novel health technologies invented here. It is not enough to financially support early stage companies. We also need to bring them to the finish line to fully benefit from investing into them - before they leave for other, potentially more attractive markets. Drug development is hard. It takes time, often pathways meander, and overall timelines are long. Healthcare Biotechnology Investors need a long breath and fair market conditions recognizing these risks. In the long-run, the overall goal to significantly improve the lives of patients and to fill medical needs is financially attractive. That’s a fact. This should encourage European policy makers and investors to take further action to continuously invest into the entire value chain being also better prepared to write the bigger checks for late-stage clinical developments. We don’t have mineral resources in Europe. But we have cutting edge medical science and amazing people that are willing and able to contribute to the growth in Europe. The Novaliq GmbH story is a small but inspiring European success story how an innovation from Heidelberg is transforming ocular therapeutics globally. www.novaliq.com

Presenting to you #VoicesThatMatter, in which we will share thoughts and insights from top biotech leaders each week. This week, we share a quote from Dr. Amit Varma Capital Advisors, one of the largest healthcare-focused investment funds in Asia. Dr. Varma brings over 30 years of experience in critical care medicine, operations, mergers and acquisitions, and private equity in both Asia and the United States. #Biotech #BioAngels #wednesdaywisdom

Congratulations to Abraham Kwon and Storme Mckop at Lowenstein Sandler LLP on advising RTW Investments, LP, investor in the Jade Biosciences' financing round read more on Global Legal Chronicle

📢 Industry Deals Update Platinum Equity is set to buy Héroux-Devtek in a $1.35 billion deal, reflecting the strong interest in the aerospace sector, driven by ongoing advancements and demand. New Harbor Capital-backed AIC acquires Big Sky, a home and specialty infusion services provider. The acquisition aligns with the growing trend towards home-based healthcare solutions, driven by patient convenience and cost-efficiency. Osceola Capital-backed Revelation Pharma acquires Taylor's Pharmacy and Key Compounding Pharmacy - Underscoring the importance of specialty pharmacies in providing customized medication solutions, which are becoming increasingly vital in personalized medicine. The Carlyle Group's recent acquisition of the Seattle Reign highlights the increasing investment potential in women's sports as viewership and fan engagement continue to rise. #PrivateEquity #TechDeals #IndustryNews #Acquisitions #Aerospace #WomenInSports #Healthcare

PÔNT's CLIENT FOCUSED GLOBAL APPROACH PÔNT's client-focused M&A approach leverages its global network to connect sellers with Private Equity Firms, Family Offices, and Strategic Buyers. By identifying and engaging suitable buyers, PÔNT ensures tailored, value-maximizing transactions. PONT's rigorous execution process and long-term relationship building provide clients with ongoing support, achieving exceptional results. #MergerAdvisoryExperts #EffectiveAcquisitionConsulting #FinancialAdvisoryForTransactions #BusinessAdvisoryForM&A #BusinessValuation #AccurateCompanyValuation #PrivateEquityDealClosures #EfficientPrivatePlacements #MADueDiligenceExperts #CrossBorderMAExpertise #MABusinessInMexico #MAInsightsForLATAM #PharmaceuticalMADealClosures #PharmaceuticalValuationServices #AutomobileGlobalIndustryMA #GAIcom #PharmaceuticalStrategicAdvisory #PharmaceuticalMarketAnalysis #MAApproach #FamilyBusinesses

Start ups are starting-up all over the United States in Cannabis & in #Psychedelic medicine. But are they “highly capitalized 💰?” Most aren’t, but if you want to reach investors at scale DM me & ask about the performance of sponsored content using Highly Capitalized. ✅ Thanks to our #proven ‘marketing funnel’ (& a bit of good luck) 🍀 —you’ll find that #strategic investor (or investors) you always wanted. ⭐️ We also work with the main Broker Dealers in New York & San Francisco on Reg A, Reg D and Reg CF #capital raises. Feel free to ask about other ways of raising capital including #debt. 👍 We’ve also succeeded in helping public companies to promote their IPO or #RTO. ☑️ We’re licensed & insured to do what we do —to help companies reach investors at #scale using our #proprietary methodologies. 🎸 Come on board to Highly Capitalized as a sponsor, sit back and let us generate leads at scale for you—of investors #active in #Cannabis

Exploring the complexities of medtech M&A: Boston Scientific’s $3.7 billion acquisition of Axonics marks a pivotal moment amid regulatory scrutiny. As the landscape evolves, this deal will serve as a key benchmark for future transactions. #Medtech #Acquisition #RegulatoryInsights #Pharma #Biotech #HealthcareInnovation #HealthcareM&A #BusinessGrowth #InvestmentTrends #financialservices #OilAndGas #EnergySector #MergersAndAcquisitions #MandA #Innovation #BusinessTrends #VCInvestments #MarketInsights #GlobalEconomy #VentureCapital #VCFunding #PrivateEquity #PrivateDebt #PrivateCapitalFunds #MergersAndAcquisitions #Finance #PrivateCredit #Investment #VentureDebt #FamilyOffice PitchBook Data, Inc. (n.d.). GLOBAL M&A Report Q1 2024. https://lnkd.in/ew4MitM2 Disclaimer: The content provided by Autori Partners on our social media platforms is for informational purposes only and should not be construed as financial advice. This information does not constitute a recommendation or offer to buy or sell any financial instruments or adopt any investment strategy. Always seek the advice of a qualified financial advisor or other relevant professional with any questions you may have regarding your personal financial situation. Investing involves risk and past performance is not indicative of future results. Please review this with your legal team or a professional to ensure it meets your specific requirements and complies with all applicable laws and regulations.

Very happy to attend the Angelini Ventures 2024 Summit in #Rome. Interesting panel, companies presentations and talk. Getting the oppportunity to meet fellow investors is always a treat. Many thanks to Tanja Dowe and Paolo Di Giorgio for making it happen. #venturecapital #investment #digitalhealth #debiopharminnovationfund